LLY

1,048.7

+1.77%↑

JNJ

202.99

+1.44%↑

ABBV

233.02

-0.35%↓

UNH

309.14

-1.49%↓

AZN

88.99

-0.51%↓

LLY

1,048.7

+1.77%↑

JNJ

202.99

+1.44%↑

ABBV

233.02

-0.35%↓

UNH

309.14

-1.49%↓

AZN

88.99

-0.51%↓

LLY

1,048.7

+1.77%↑

JNJ

202.99

+1.44%↑

ABBV

233.02

-0.35%↓

UNH

309.14

-1.49%↓

AZN

88.99

-0.51%↓

LLY

1,048.7

+1.77%↑

JNJ

202.99

+1.44%↑

ABBV

233.02

-0.35%↓

UNH

309.14

-1.49%↓

AZN

88.99

-0.51%↓

LLY

1,048.7

+1.77%↑

JNJ

202.99

+1.44%↑

ABBV

233.02

-0.35%↓

UNH

309.14

-1.49%↓

AZN

88.99

-0.51%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Open

4.2 -1.87

Buy Sell

Overview

Share price change

24h

Current

Min

4.11

Max

4.39

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
EPS	-0.47
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+230.17% upside

Market Stats
By TradingEconomics
Market Cap	-26M 229M
Previous open	6.07
Previous close	4.2

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 lis 2025, 19:25 UTC

Acquisitions, Mergers, Takeovers

Canada Says Anglo American's Pledges to Secure Teck Resources Deal Not Enough -- 2nd Update

18 lis 2025, 18:09 UTC

Acquisitions, Mergers, Takeovers

Canada Says Anglo American's Pledges to Secure Teck Resources Deal Not Enough -- Update

18 lis 2025, 17:39 UTC

Acquisitions, Mergers, Takeovers

Canada Says Anglo American's Pledges to Secure Teck Resources Deal Not Enough

18 lis 2025, 16:25 UTC

Major Market Movers

Diginex Rises on Deal With Digital Asset Platform Evident

18 lis 2025, 23:56 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

18 lis 2025, 23:39 UTC

Market Talk

Nikkei May Rise on Bargain-Hunting Interest -- Market Talk

18 lis 2025, 22:59 UTC

Market Talk

FireFly Metals Can Build Bigger Operation at Green Bay -- Market Talk

18 lis 2025, 22:08 UTC

Market Talk

Sandfire's Kalkaroo Project Push Adds to Copper M&A Surge -- Market Talk

18 lis 2025, 22:03 UTC

Acquisitions, Mergers, Takeovers

Meta Defeats FTC's Antitrust Case Alleging Social-Media Monopoly -- 3rd Update

18 lis 2025, 22:03 UTC

Earnings

These Stocks Moved the Most Today: Nvidia, Microsoft, Home Depot, Cloudflare, Energizer, Honeywell, Medtronic, Klarna, and More -- Barrons.com

18 lis 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

18 lis 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18 lis 2025, 21:15 UTC

Market Talk

Private High-Grade Credit Market Is Changing, BlackRock Says -- Market Talk

18 lis 2025, 20:46 UTC

Market Talk

U.S. Natural Gas Futures Edge Up on Weather Outlook -- Market Talk

18 lis 2025, 20:13 UTC

Market Talk

Distillate Supply Concerns Pull Crude Futures Higher -- Market Talk

18 lis 2025, 19:48 UTC

Market Talk

Gold and Silver Turn Lower on Fed Outlook -- Market Talk

18 lis 2025, 19:19 UTC

Acquisitions, Mergers, Takeovers

Anheuser-Busch InBev Nears $700 Million Deal for Party Punch Maker BeatBox -- WSJ

18 lis 2025, 19:19 UTC

Acquisitions, Mergers, Takeovers

Anheuser-Busch InBev in Talks to Buy Party Punch Maker BeatBox, Sources Say -- WSJ

18 lis 2025, 19:19 UTC

Acquisitions, Mergers, Takeovers

AB InBev-BeatBox Deal Could Come Together Soon, Sources Say -- WSJ

18 lis 2025, 19:19 UTC

Acquisitions, Mergers, Takeovers

AB InBev Deal Would Value BeatBox At Around $700M, Sources Say -- WSJ

18 lis 2025, 18:29 UTC

Earnings

These Stocks Are Moving the Most Today: Nvidia, Microsoft, Home Depot, Cloudflare, Energizer, Honeywell, Medtronic, Klarna, and More -- Barrons.com

18 lis 2025, 18:18 UTC

Market Talk

Ethanol Demand Expected to Boost Corn Futures -- Market Talk

18 lis 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18 lis 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

18 lis 2025, 17:19 UTC

Market Talk

Earnings

Good Weather Was Bad News for Home Depot's 3Q -- Market Talk

18 lis 2025, 17:06 UTC

Earnings

Medtronic Stock Rises After Earnings. What Caught Investors' Attention. -- Barrons.com

18 lis 2025, 16:06 UTC

Acquisitions, Mergers, Takeovers

Intuit Stock Gains on OpenAI Deal. ChatGPT Is Coming to TurboTax. -- Barrons.com

18 lis 2025, 15:59 UTC

Earnings

Home Depot Cuts Outlook as Home Improvement Slowdown Continues -- Update

18 lis 2025, 15:35 UTC

Acquisitions, Mergers, Takeovers

Eni: Acquisition Adds to Plenitude's Installed-Capacity Targets, Bolsters France Presence

18 lis 2025, 15:35 UTC

Acquisitions, Mergers, Takeovers

Eni: Portfolio Comprises Capacity of Around 760MW in Operation

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

230.17% upside

12 Months Forecast

Average 13.57 USD 230.17%

High 25 USD

Low 8 USD

Based on 9 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.